ZHANG CLINIC®
PROTOCOLS
Herb Distribution @
www.hepapro.com



Zhang Clinic
20 E. 46th Street
Suite 1402
New York,  NY 10017

Tel:  (212) 573-9584 
Fax: (212) 573-6045

 
This is a password-protected private information web. Materials presented here is only intended for viewing by Zhang Clinic employees, affiliated professional practitioners and clinic patients.
Hepatitis C
 
Lyme Disease
Hepatitis Peripheral Complications Colitis /Crohn's Disease (Inflammatory Bowel Syndrome)
Non-Alcoholic Steatohepatitis (NASH): Fatty Liver Liver Cirrhosis Related Conditions
Alcoholic Liver Disease  
Auto-Immune Hepatitis
Cholestatic Hepatitis
SinoMed Research Home
About Dr. Zhang
Herbs

ZHANG CLINIC featured again in
Dr. Weil's "Self Healing" newsletter

Click here to read the excerpt

Formula List
AI # 3 Capsule
Allicin Capsule
Artemisia Capsule
Artemisia 2 Capsule
(Double Potency)
BM Capsule
Capillaris Combination
Circulation P Capsule
Copmine Formula
Coptis Capsule
Cordyceps Capsule
DH-Artemisinin Capsule
Gall Formula 1
Gineseng and Atractylodes Formula
Glycyrrhizin Capsule
GL2
Hepa Formula 1A
Hepa Formula 2
HerbLipido
HerbSom Capsule
HerbZac Capsule
HH Tablets
HH 2 Capsule
(Double Potency)
Ligustrin Capsule
Milk Thistle Plus
MVM Formula
Olivessence Capsule
Puerarin Capsule
R-5081 Capsule
R-OBG Capsule
Schisandra Plus
Sedin
TGP formula
Yunan Paiyao Capsule
 
TGP Formula
 
Recommended Daily Dose:
2 Capsules, 3 Times a Day

(Individual Dosage May Vary. Please Your Consult Health Care Professional)


Orignial Herb: Radix Paeoniae Alba

Active ingredient used: Total Glucosides of Peony (TGP)

 

Pharmacological Actions:

  1. Effects on Immunity:

TGP has been shown to have selective regulatory effects on immune reactions. At a high dose (200mg/kg/day), it has shown to enhance delayed hypersensitivity (DH) in mice. Reactions from a low dose (5mg/kg/day) maybe enhancing, suppressing, or contain no effect, depending on the original immune status. TGP has demonstrated marked antagonistic effects on DH suppression induced by cytoxan and no obvious effect on DH suppression induced by dexamethasone (DXM). At a dose of 5mg/kg/day, there were no effects shown in normal mice antibody production. However, when the same dose was used in mice with suppressed immunity induced by cytoxan, antibody production returned to normal levels. At a dose level of 40mg/kg/day injected intraperitoneally, TGP promoted phagocytosis of phagocytes in the abdominal cavity in mice (Wei WS et al., 1987).

TGP can also enhance the induction of specific or non-specific T regulatory cells, both in vitro and in vivo in a concentration-dependent manner. The effect is related to its ability to stimulate macrophages activities. TGP’s immune regulatory effects are related to its adjustment effects on the Th/Ts ratio. (Wang XW et al., 1991,1990)

TGP at a very low concentration (45 to 450 ng/ml) can promote lymph cell proliferation induced by ConA in mice. It can also induce human cord white blood cells to produce a-interferon (Zhang H et al., 1988). In addition, it can promote interferon-g secretion and has shown to have anti-viral effects (Xiao SX et al., 1991).

 

  1. Anti-inflammatory effects:

TGP has shown to have suppressive effect on the production of leukotrienes B4 by macrophages. This was shown to be the equivalent of the effect induced by the same dose of non-steroid-anti-inflammatory flufenamic acid. TGP at a concentration range of 0.001 to 100mg/L can suppress leukotrienes Bproduction and its IC50 was 0.66mg/L. Its anti-inflammatory and immune regulatory actions are related to its effects on the production of leukotrienes B4. (Li J et al., 1992)

TGP has shown to have therapeutic effects on the adjuvant arthritis. This is based on its concentration-dependent (at the concentration range of 0.09 to 11.25 mg/ml) suppressive actions on the secretion of IL-1 and H2O2 by macrophages. The suppressive actions peak at the concentration of 11.25 mg/ml. When the concentration increased above 11.25 mg/ml, the suppressive effects started to decrease. (Liang JS et al., 1990)

 

  1. Effects on the Liver:
    In animal studies conducted with a dose of 40 to 80 mg/kg/day injected intraperitoneally, TGP showed obvious suppressive effects on the elevation of ALT and LDH in the serum and no effects on the elevation of AST. The same dose also demonstrated protective effects on liver tissue damage induced by CCl4. (Wang YJ et al., 1988)

     
  2. Other Actions:
    TGP has demonstrated anti-free radicals and anti-oxidant effects. (Gao BB et al., 1991) Paeoniflorin is one of the glucosides extracted from the peony root and it has shown to have apoptosis inducing effects on human hepatoma cell lines HepG-2. The apoptosis effect is related to the up-regulation and down-regulation of anti-apoptosis genes. Therefore, TGP it has the potential to be used as an anti-fibrosis and anti-liver cancer treatment with virtually no toxicity. (Han XS et al., 2006) TGP also demonstrated pain suppressing effects in the dose range of 1 to 40mg/kg. When TGP was used together with morphine, the pain suppressing effects were demonstrated to be greater than morphine used alone. TGP also demonstrated anti-spastic effects and the ability to resolve cramping of the intestines. (Wang YJ et al., 1988)

     
  3. Toxicity:
    The oral dose of LD50 in mice was 81.1 grams (whole herb)/kg. The TGP for mice the LD50 was 230mg/kg injected into the abdominal cavity. Infusing 2500mg/kg into mice stomach daily for one week showed no intoxication effects. It has also been tested for mutation inducing actions and no mutagenesis effects were found. Overall, TGP was showed to have almost no toxicity at high to low doses. (She SZ et al., 1990)  

     

Clinical Studies:

  1. Rheumatoid Arthritis:

Wang ZJ et al., compared the efficacy of TGP and methotrexate (MTX) in treating rheumatoid arthritis patients. It was found that TGP and methotrexate had similar effects and there were no significant differences in the clinical outcome (p>0.05) (Wang ZJ et al., 1994). Wang Yan et al., also found that combining TGP and MTX achieved even better clinical results in treating rheumatoid arthritis. This combination demonstrated the same efficacy levels as MTX combined with sufasalazine (SSZ), but with less side-effects. TGP combined with MTX achieved more favorable therapeutic effects, demonstrating quicker initiation with less toxicity and side effects. (Wang Y et al., 2007)

 

  1. Sjogren Syndrome (SS):

Zhang HF et al., reported that TGP has been used for treating SS and observed 27 cases compared with a control group of 20 cases that used hydroxychloroquine sulfate (HCQs). Within a two-year treatment course, it was found that the efficacy of TGP was equivalent to that of HCQs in treating non-systemic involved SS. TGP showed less side effects and initiating time being 6 to 12 months. (Zhang HF et al., 2007)

 

  1. Geriatric Conditions: 

TGP showed various beneficial effects on general health and also immunity. In randomized, double blind, and placebo controlled trials, 40 cases were given TGP Capsule (500mg) 1 capsule, three times a day. Most members of the study were elderly patients with chronic respiratory track conditions. The TGP treated group showed much better effects in controlling cough and asthma, expelling phlegm, and immune functions were showed to be better compared to placebo. (Zhang XG et al., 1988)

 

  1. Systemic Lupus Erythematosus (SLE):

Shuai ZW et al., reported that in a randomized, double-blind and placebo-controlled test, TGP combined with concomitant glucocorticoid (GC) significantly improved the therapeutic results, reduced the necessary dose of GC with much less adverse reactions in the treatment group compared with the placebo group. It was found that when TGP was combined with GC, the GC dose can be reduced, which makes long-term treatment safer with less harmful effects. (Shuai AW et al., 2003)  

Package:

Every capsule contains 104mg of TGP and extracts from the Radix Paeoniae Alba. Every bottle contains 90 capsules.

Dosage:            Take two capsules, three times a day.

 

 

References:

Gao BB et al., J. of Anhui Medical University , 1991, 26(3):234

Li J et al., China Bulletin of Pharmacology, 1992, 8(1):36-38

Liang JS et al., Chinese J of Pharmacology and Toxicology, 1990, 5(2):153-154

She SZ et al., The J of Chinese Pharmaceutical Industry, 1990; 21(11):496

Shuai ZW et al., Clinical study on effect of total glucosides of peony in treating systemic lupus erythematosus as adjuvant treatment, CJITWM, 2003, 23(3):188-191

Wang XW et al., J. of Anhui Medical University , 1991, 26(2):147

Wang XW et al., China Bulletin of Pharmacology, 1990, 6(6):363

Wang Yan et al., Clinical observation on effect of total glucosides of paeony combined with methotrexate on rheumatoid arthritis, CJITWM, 2007, 27(9):839-840

Wang YJ et al., China Bulletin of Pharmacology, 1988, 4(6):362-364

Wang ZJ et al., Clinical and pharmacological studies of Total Glucoside of Peony treatment for rheumatoid arthritis, China Bulletin of Pharmacology, 1994, 10(2):117-122

Wei WS etal., China Bulletin of Pharmacology, 1987, 3(3):148-151

Xiao SX et al., J. of Anhui Medical University , 1991, 26(3):213

Yan XS et al., Study on apoptosis of human hepatoma cell line hepG2 induced by paeoniflorin, Chin J Inte Trad Western Med on Liver Diseases, 2006, 16(1):18-20

Zhang H et al., J. of Anhui Medical University , 1988, 23(2):144

Zhang HF et al., Clinical observation on effect of total glucosides of paeony in treating patients with non-systemic involved Sjogren syndrome, CJITWM, 2007, 27(7):596-598

Zhang XJ et al., China Bulletin of Pharmacology, 1988, 4(5):314-315